SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

(S)-HDAC-42

Item No. 13277

CAS Registry No.:	935881-37-1
Formal Name:	N-[4-[(hydroxyamino)carbonyl]phenyl]-αS-(1-methylethyl)-benzeneacetamide
Synonyms:	AR42, OSU-HDAC 42
MF:	$C_{18}H_{20}N_2O_3$
FW:	312.4
Purity:	≥95%
UV/Vis.:	λ_{max}: 206, 272 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(S)-HDAC-42 is supplied as a crystalline solid. A stock solution may be made by dissolving the (S)-HDAC-42 in the solvent of choice, which should be purged with an inert gas. (S)-HDAC-42 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of (S)-HDAC-42 in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

(S)-HDAC-42 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (S)-HDAC-42 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. (S)-HDAC-42 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

(S)-HDAC-42 is a histone deacetylase (HDAC) inhibitor (IC_{50} = 16 nM).[1] It increases acetylation of histone H3 in DU145 prostate cancer cells when used at concentrations ranging from 0.1 to 2.5 µM. (S)-HDAC-42 decreases viability of DU145 cells (IC_{50} = 0.11 µM). It induces cell cycle arrest at the G_1 phase in A2780 ovarian cancer cells when used at a concentration of 0.5 µM.[2] (S)-HDAC-42 (25 mg/kg per day or 50 mg/kg every other day) decreases tumor volume in a PC3 prostate cancer mouse xenograft model.[3]

References

1. Lu, Q., Wang, D.S., Chen, C.S., *et al.* Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. *J. Med. Chem.* **48(17)**, 5530-5535 (2005).
2. Yang, Y.-T., Balch, C., Kulp, S.K., *et al.* A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. *Neoplasia* **11(6)**, 552-563 (2009).
3. Kulp, S.K., Chen, C.S., Wang, D.S., *et al.* Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. *Clin. Cancer Res.* **12(17)**, 5199-5206 (2006).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM